Adam LaBonte is a seasoned veteran in the world of clinical oncology and NGS technologies. With over a decade of experience in sales and support teams, Adam has a proven track record of driving growth and success at multiple leading companies.
At ArcherDx, Adam was a key member of the team that helped launch the company’s first NGS products in North America, including targeted panels, custom assays, and secondary analysis. He played a critical role in the commercialization of these products and helped establish ArcherDx as a leader in the industry of clinical NGS diagnostics.
At QIAGEN, Adam led the clinical NGS team that supported NGS instrumentation and targeted assays for use on multiple platforms. With his expertise and guidance, the team was able to drive growth and increase the adoption of these technologies in the clinical space.
Most recently, at Pillar Biosciences, Adam led a team that sold and supported IVD and RUO products internationally. He was instrumental in building Pillar’s first FDA-approved test, OncoReveal Dx, and helped the company establish a strong presence in the clinical oncology market domestically and internationally.
Adam enjoys spending his free time skiing and mountain biking while enjoying all that Montana has to offer with his wife and three children.